Physician profile
Ryan M Sato
NPI 1235443995
$225,563.55
in general payments reported to CMS, 2019-2025
27 companies · $145K in 2025
The $145K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $1,133 · 2021: $2,020 · 2022: $2,473 · 2023: $24K · 2024: $50K · 2025: $145K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Consulting Fee: $39K · Honoraria: $23K · Travel and Lodging: $20K · Food and Beverage: $18K · Education: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $117,654.00 |
| Consulting Fee | $39,409.00 |
| Honoraria | $22,505.30 |
| Travel and Lodging | $20,190.82 |
| Food and Beverage | $18,168.26 |
| Education | $644.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $75,353.97 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $37,249.82 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $33,147.65 | 2019-2025 | |
| Organon LLC | $27,564.82 | 2025 | Vtama |
| Lilly USA, LLC | $16,169.66 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $13,700.25 | 2022-2025 | Sotyktu |
| Abbvie INC. | $5,548.02 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $4,806.44 | 2020-2025 | |
| Dermavant Sciences, INC. | $3,322.57 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $1,685.77 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $1,301.73 | 2019-2025 | Ilumya, Winlevi |
| Amgen INC. | $1,236.53 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $784.03 | 2019-2025 | |
| Array Biopharma INC | $720.00 | 2025 | Braftovi |
| Incyte Corporation | $719.46 | 2022-2025 | Opzelura, Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $611.78 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $489.74 | 2020-2025 | Simponi Aria, Stelara, Simponi |
| Ucb, INC. | $463.93 | 2020-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $259.97 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.37 | 2019-2024 | Siliq, Duobrii |
| Dermira, INC. | $61.69 | 2019-2020 | |
| Merz North America, INC. | $57.85 | 2019-2022 | |
| Kyowa Kirin, INC. | $44.91 | 2021-2022 | |
| Allergan, INC. | $44.60 | 2019-2020 | |
| Celgene Corporation | $41.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $22.90 | 2020 | |
| Almirall LLC | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.